Market Research Logo

Diabetic Neuropathic Pain - Pipeline Review, H2 2016

Diabetic Neuropathic Pain - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Diabetic Neuropathic Pain - Pipeline Review, H2 2016’, provides an overview of the Diabetic Neuropathic Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Neuropathic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Neuropathic Pain and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Diabetic Neuropathic Pain
  • The report reviews pipeline therapeutics for Diabetic Neuropathic Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Diabetic Neuropathic Pain therapeutics and enlists all their major and minor projects
  • The report assesses Diabetic Neuropathic Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Diabetic Neuropathic Pain
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathic Pain
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Diabetic Neuropathic Pain pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Diabetic Neuropathic Pain Overview
Therapeutics Development
Pipeline Products for Diabetic Neuropathic Pain - Overview
Pipeline Products for Diabetic Neuropathic Pain - Comparative Analysis
Diabetic Neuropathic Pain - Therapeutics under Development by Companies
Diabetic Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes
Diabetic Neuropathic Pain - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Diabetic Neuropathic Pain - Products under Development by Companies
Diabetic Neuropathic Pain - Products under Investigation by Universities/Institutes
Diabetic Neuropathic Pain - Companies Involved in Therapeutics Development
APT Therapeutics, Inc.
Astellas Pharma Inc.
BioDelivery Sciences International, Inc.
Bristol-Myers Squibb Company
Centrexion Therapeutics Corp
Chromocell Corporation
Daiichi Sankyo Company, Limited
Grunenthal GmbH
Hydra Biosciences, Inc.
Immune Pharmaceuticals Inc.
Laboratorios Del Dr. Esteve S.A.
Lohocla Research Corporation
Novaremed
PeriphaGen, Inc.
Pharmaleads SA
Prismic Pharmaceuticals, Inc.
Relmada Therapeutics, Inc.
Sphaera Pharma Pvt. Ltd.
Theravasc, Inc.
Diabetic Neuropathic Pain - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(amitriptyline + ketamine hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diclofenac sodium + triclocarban) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APT-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AS-1069562 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-8464 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cebranopadol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
clonidine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CNTX-6016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EC-5026 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GERP-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HX-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Kindolor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mepivacaine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mirogabalin besylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MR-309 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NRD-135SE1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
palmidrol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PGN-305 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-37 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Kv7.2 for Neuropathic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sodium nitrite SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Diabetic Neuropathic Pain - Dormant Projects
Diabetic Neuropathic Pain - Discontinued Products
Diabetic Neuropathic Pain - Product Development Milestones
Featured News & Press Releases
Mar 04, 2016: BioDelivery Sciences to provide an update on Clonidine Topical Gel at the Cowen And Company 36th Annual Healthcare Conference and the 28th Annual Roth Conference
Jan 06, 2016: Hydra Biosciences to Present at the 8th Annual Biotech Showcase Conference in San Francisco on Jan. 11
Sep 28, 2015: Pharmaleads Announces the Opening of French Sites in Its International Phase IIa Clinical Study of PL37
Apr 22, 2015: Pharmaleads Announces the Inclusion of the First Patient in Phase IIa Study of Oral PL37 for Pain in Diabetic Neuropathy
Mar 30, 2015: BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development
Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin
Dec 08, 2014: BioDelivery Sciences Announces Completion of Randomization in Phase 3 Trial of Clonidine Topical Gel for the Treatment of Painful Diabetic Neuropathy
Aug 06, 2014: BioDelivery Sciences Provides Update on Ongoing Phase 3 Pivotal Trial for Clonidine Topical Gel for Painful Diabetic Neuropathy
Oct 30, 2012: Drug Offers New Pain Management Therapy For Diabetics, Study Finds
Jun 04, 2012: EpiCept Receives Scientific Advice From EMA For AmiKet CIPN Program
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Diabetic Neuropathic Pain, H2 2016
Number of Products under Development for Diabetic Neuropathic Pain - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Diabetic Neuropathic Pain - Pipeline by APT Therapeutics, Inc., H2 2016
Diabetic Neuropathic Pain - Pipeline by Astellas Pharma Inc., H2 2016
Diabetic Neuropathic Pain - Pipeline by BioDelivery Sciences International, Inc., H2 2016
Diabetic Neuropathic Pain - Pipeline by Bristol-Myers Squibb Company, H2 2016
Diabetic Neuropathic Pain - Pipeline by Centrexion Therapeutics Corp, H2 2016
Diabetic Neuropathic Pain - Pipeline by Chromocell Corporation, H2 2016
Diabetic Neuropathic Pain - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
Diabetic Neuropathic Pain - Pipeline by Grunenthal GmbH, H2 2016
Diabetic Neuropathic Pain - Pipeline by Hydra Biosciences, Inc., H2 2016
Diabetic Neuropathic Pain - Pipeline by Immune Pharmaceuticals Inc., H2 2016
Diabetic Neuropathic Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2016
Diabetic Neuropathic Pain - Pipeline by Lohocla Research Corporation, H2 2016
Diabetic Neuropathic Pain - Pipeline by Novaremed, H2 2016
Diabetic Neuropathic Pain - Pipeline by PeriphaGen, Inc., H2 2016
Diabetic Neuropathic Pain - Pipeline by Pharmaleads SA, H2 2016
Diabetic Neuropathic Pain - Pipeline by Prismic Pharmaceuticals, Inc., H2 2016
Diabetic Neuropathic Pain - Pipeline by Relmada Therapeutics, Inc., H2 2016
Diabetic Neuropathic Pain - Pipeline by Sphaera Pharma Pvt. Ltd., H2 2016
Diabetic Neuropathic Pain - Pipeline by Theravasc, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Diabetic Neuropathic Pain - Dormant Projects, H2 2016
Diabetic Neuropathic Pain - Dormant Projects (Contd..1), H2 2016
Diabetic Neuropathic Pain - Dormant Projects (Contd..2), H2 2016
Diabetic Neuropathic Pain - Discontinued Products, H2 2016
Diabetic Neuropathic Pain - Discontinued Products (Contd..1), H2 2016
List of Figures
Number of Products under Development for Diabetic Neuropathic Pain, H2 2016
Number of Products under Development for Diabetic Neuropathic Pain - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report